JP2009522369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009522369A5 JP2009522369A5 JP2008549592A JP2008549592A JP2009522369A5 JP 2009522369 A5 JP2009522369 A5 JP 2009522369A5 JP 2008549592 A JP2008549592 A JP 2008549592A JP 2008549592 A JP2008549592 A JP 2008549592A JP 2009522369 A5 JP2009522369 A5 JP 2009522369A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- composition according
- transition period
- bisphosphonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 30
- 230000007704 transition Effects 0.000 claims 12
- 229940122361 Bisphosphonate Drugs 0.000 claims 9
- 150000004663 bisphosphonates Chemical class 0.000 claims 9
- 238000009097 single-agent therapy Methods 0.000 claims 6
- 229940121682 Osteoclast inhibitor Drugs 0.000 claims 5
- 102000014128 RANK Ligand Human genes 0.000 claims 5
- 108010025832 RANK Ligand Proteins 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 230000000010 osteolytic effect Effects 0.000 claims 4
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 4
- 229960004276 zoledronic acid Drugs 0.000 claims 4
- 241001529936 Murinae Species 0.000 claims 3
- 238000009175 antibody therapy Methods 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 206010065687 Bone loss Diseases 0.000 claims 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 2
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 claims 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims 1
- 229940062527 alendronate Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960002286 clodronic acid Drugs 0.000 claims 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 229940009626 etidronate Drugs 0.000 claims 1
- 229940015872 ibandronate Drugs 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 229940046231 pamidronate Drugs 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 1
- 229940089617 risedronate Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940019375 tiludronate Drugs 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75694406P | 2006-01-05 | 2006-01-05 | |
| US60/756,944 | 2006-01-05 | ||
| PCT/US2007/000405 WO2007081879A2 (en) | 2006-01-05 | 2007-01-04 | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012186613A Division JP2012229271A (ja) | 2006-01-05 | 2012-08-27 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009522369A JP2009522369A (ja) | 2009-06-11 |
| JP2009522369A5 true JP2009522369A5 (enExample) | 2011-02-10 |
| JP5580535B2 JP5580535B2 (ja) | 2014-08-27 |
Family
ID=38219019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008549592A Active JP5580535B2 (ja) | 2006-01-05 | 2007-01-04 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
| JP2012186613A Pending JP2012229271A (ja) | 2006-01-05 | 2012-08-27 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012186613A Pending JP2012229271A (ja) | 2006-01-05 | 2012-08-27 | 癌転移および癌転移に関連する骨量減少を予防および処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090246208A1 (enExample) |
| EP (2) | EP1984024A2 (enExample) |
| JP (2) | JP5580535B2 (enExample) |
| KR (1) | KR20080083187A (enExample) |
| CN (1) | CN101534858A (enExample) |
| AU (1) | AU2007205048B2 (enExample) |
| BR (1) | BRPI0706314A2 (enExample) |
| CA (1) | CA2636149A1 (enExample) |
| IL (1) | IL192568A0 (enExample) |
| RU (1) | RU2470665C2 (enExample) |
| TW (1) | TW200738262A (enExample) |
| WO (1) | WO2007081879A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| WO2010062401A2 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using csf1r extracellular domain fusion molecules |
| AU2010329934B2 (en) | 2009-12-10 | 2015-05-14 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human CSF1R extracellular domain 4 and their use |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| MX355418B (es) | 2010-05-04 | 2018-04-18 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| AU2012285875B2 (en) | 2011-07-18 | 2016-11-10 | Morphosys Ag | Use of c-Fms antagonists |
| WO2013033206A2 (en) * | 2011-08-29 | 2013-03-07 | University Of Rochester | Compositions and methods for inhibiting ccl3 |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| CN103044555B (zh) * | 2012-07-05 | 2016-08-31 | 雷克塞德（苏州）生物医药有限公司 | 包含cFms胞外片段的融合蛋白质及其制备方法和应用 |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AU2014229505B2 (en) * | 2013-03-15 | 2020-02-27 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| BR112015025622A2 (pt) | 2013-04-12 | 2017-07-18 | Morphosys Ag | anticorpo ou fragmento de anticorpo isolado, composição farmacêutica, ácido nucleico, vetor, e célula hospedeira isolada |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| RU2551622C1 (ru) * | 2014-02-20 | 2015-05-27 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения опухолей позвоночника |
| KR20230086809A (ko) | 2014-06-23 | 2023-06-15 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법 |
| BR112017008914A2 (pt) | 2014-10-29 | 2018-01-16 | Five Prime Therapeutics, Inc. | método para tratar câncer, composição e uso da composição |
| KR20170096187A (ko) | 2014-12-22 | 2017-08-23 | 파이브 프라임 테라퓨틱스, 인크. | Pvns를 치료하기 위한 항-csf1r 항체 |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| RU2609871C1 (ru) * | 2015-08-10 | 2017-02-06 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) | Противоопухолевое средство |
| RU2631486C1 (ru) * | 2016-06-17 | 2017-09-22 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ получения противоопухолевого средства против метастазов костей в виде конъюгата белка-цитокина и аминобисфосфоната |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| WO2018115051A1 (en) | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| BR112020004879A2 (pt) | 2017-09-13 | 2020-09-15 | Five Prime Therapeutics, Inc. | métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer |
| JP2021534101A (ja) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス， インコーポレイテッド | Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| US4544545A (en) * | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4929700A (en) | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| ATE141290T1 (de) | 1989-02-10 | 1996-08-15 | Cetus Oncology Corp | M-csf-monoklonale antikörper, die ein neutralisierendes konformationales epitop erkennen |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US20020111461A1 (en) | 1999-05-21 | 2002-08-15 | Todd C. Somers | Low molecular weight peptidomimetic growth hormone secretagogues |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6025146A (en) | 1995-06-05 | 2000-02-15 | Chiron Corporation | Identification of M-CSF agonists and antagonists |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| RU2153358C1 (ru) * | 1999-11-10 | 2000-07-27 | Центральный научно-исследовательский рентгенорадиологический институт МЗ России | Способ лечения остеолитических метастазов |
| US20030199531A1 (en) | 2001-07-19 | 2003-10-23 | Todd Wipke | YIGSR peptidomimetics and methods for using the same |
| CA2468687A1 (en) * | 2001-12-13 | 2003-06-26 | Merck & Co., Inc. | Liquid bisphosphonate formulations for bone disorders |
| HRP20050371B1 (hr) * | 2002-09-27 | 2014-09-26 | Zentaris Gmbh | Oblik za primjenu farmaceutiski djelatnih peptida s produljenim oslobađanjem djelatnog sastojka i postupak za njihovu proizvodnju |
| EP1572106B1 (en) * | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| DK2311873T3 (en) * | 2004-01-07 | 2018-11-26 | Novartis Vaccines & Diagnostics Inc | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
| JP5457671B2 (ja) * | 2005-07-28 | 2014-04-02 | ノバルティス アーゲー | Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用 |
| MX2008013531A (es) * | 2006-04-20 | 2009-01-20 | Janssen Pharmaceutica Nv | Inhibidores de c-fms cinasa. |
-
2007
- 2007-01-04 JP JP2008549592A patent/JP5580535B2/ja active Active
- 2007-01-04 CN CNA2007800067993A patent/CN101534858A/zh active Pending
- 2007-01-04 CA CA002636149A patent/CA2636149A1/en not_active Abandoned
- 2007-01-04 AU AU2007205048A patent/AU2007205048B2/en active Active
- 2007-01-04 RU RU2008132150/15A patent/RU2470665C2/ru not_active IP Right Cessation
- 2007-01-04 KR KR1020087018238A patent/KR20080083187A/ko not_active Abandoned
- 2007-01-04 BR BRPI0706314-8A patent/BRPI0706314A2/pt not_active IP Right Cessation
- 2007-01-04 WO PCT/US2007/000405 patent/WO2007081879A2/en not_active Ceased
- 2007-01-04 EP EP07716432A patent/EP1984024A2/en not_active Withdrawn
- 2007-01-04 US US12/159,665 patent/US20090246208A1/en not_active Abandoned
- 2007-01-04 EP EP13168106.6A patent/EP2705854A1/en not_active Withdrawn
- 2007-01-05 TW TW096100615A patent/TW200738262A/zh unknown
-
2008
- 2008-07-02 IL IL192568A patent/IL192568A0/en unknown
-
2012
- 2012-08-27 JP JP2012186613A patent/JP2012229271A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009522369A5 (enExample) | ||
| RU2008132150A (ru) | Способы профилактики и лечения ракового метастаза и разрежения кости, связанного с раковым метастазом | |
| JP2013500995A5 (enExample) | ||
| Xu et al. | Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? | |
| Watts et al. | Long-term use of bisphosphonates in osteoporosis | |
| JP6067466B2 (ja) | 骨粗鬆症の治療および予防用のビスホスホン酸 | |
| Yamashita et al. | Antiresorptives and osteonecrosis of the jaw | |
| CA2438848A1 (en) | Compositions for delivering bisphosphonates | |
| CN104039828B (zh) | 通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法 | |
| CZ20024134A3 (cs) | Farmaceutické prostředky obsahující bisfosfonáty pro léčení stavů s abnormálně zvýšeným kostním obratem | |
| RU2006140888A (ru) | Лекарственные формы на основе бисфосфонатов | |
| JP2006506365A5 (enExample) | ||
| RU2003133773A (ru) | Фармацевтическое применение бисфосфонатов | |
| HRP20161170T1 (hr) | Pripravak tekućine za dijalizu koji sadrži tvari za inhibiciju kristalizacije | |
| JP2005530819A5 (enExample) | ||
| JP2006500401A5 (enExample) | ||
| HRP20221319T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| Russell | Ibandronate: pharmacology and preclinical studies | |
| F. Barghash et al. | Pathophysiology of metastatic bone disease and the role of the second generation of bisphosphonates: from basic science to medicine | |
| RU2003100503A (ru) | Способ введения бисфосфонатов | |
| Anghel et al. | Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease | |
| Bartl et al. | Bisphosphonates (BPs) | |
| Bartl | Bisphosphonates (BP) and Denosumab | |
| JP2009508834A5 (enExample) | ||
| Adverse Drug Reactions Advisory Committee | Bisphosphonates and ocular inflammation |